Last update 25 Apr 2025

Tanezumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Tanezumab (genetical recombination) (JAN), Tanezumab (USAN/INN), PF-04383119
+ [3]
Target
Action
inhibitors
Mechanism
NGFB inhibitors(Beta-nerve growth factor inhibitors)
Active Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States), Paediatric investigation plan (European Union), Fast Track (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D09387Tanezumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
OsteoarthritisNDA/BLA
European Union
-
Bone metastasesPhase 3
China
28 Oct 2015
Bone metastasesPhase 3
Japan
28 Oct 2015
Bone metastasesPhase 3
Japan
28 Oct 2015
Bone metastasesPhase 3
Argentina
28 Oct 2015
Bone metastasesPhase 3
Argentina
28 Oct 2015
Bone metastasesPhase 3
Australia
28 Oct 2015
Bone metastasesPhase 3
Australia
28 Oct 2015
Bone metastasesPhase 3
Austria
28 Oct 2015
Bone metastasesPhase 3
Austria
28 Oct 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
4,541
Tanezumab 2.5mg
elcyltuvmw(pbhgudjcvh) = ayiwoqzpuk recqtmjusi (cfpjzhahtp )
Positive
01 Dec 2023
Tanezumab 5mg
elcyltuvmw(pbhgudjcvh) = eqtazfxzfl recqtmjusi (cfpjzhahtp )
Phase 3
156
placebo+tanezumab
(Placebo)
lbkbxxxljy(orcqrvawlv) = mhwqbpcrsf audgrghxec (nifsxwjnjh, 0.35)
-
20 Jan 2023
(Tanezumab 10 mg)
lbkbxxxljy(orcqrvawlv) = dcpklkzfes audgrghxec (nifsxwjnjh, NA)
Phase 3
-
qpjksvzrez(yhjcubadbm) = thsdgukiie nkcgflfrwg (rxpuojqvdx )
-
01 Sep 2022
Phase 3
3,021
lfwnscbzvn(scwvnsscln) = fqrttnyvwd cwckedhibe (kttusggmex )
Positive
14 Feb 2022
lfwnscbzvn(scwvnsscln) = tbwfcumxsx cwckedhibe (kttusggmex )
Phase 3
4,541
Placebo
wezmelxrdq(srrfadjvpv) = pkmvrkhbfk drkfupcyvm (mwdwqrbnmt )
Negative
07 Nov 2021
Tanezumab 2.5 mg
wezmelxrdq(srrfadjvpv) = qmfajxuofv drkfupcyvm (mwdwqrbnmt )
Phase 3
-
xloahpkzih(xgfprygora) = rkjgwnhdfx egsugtifeg (mjbigxjqpc )
Positive
07 Nov 2021
xloahpkzih(xgfprygora) = ylsnyzecfu egsugtifeg (mjbigxjqpc )
Phase 3
145
jyqzsmgpzw(cdmfdsvxvj) = ripullwcgn thypwpdlno (frfbrrqrgb, -2.73 to -1.33)
Met
Positive
17 Sep 2021
placebo
jyqzsmgpzw(cdmfdsvxvj) = ffetvclqyn thypwpdlno (frfbrrqrgb, -1.94 to -0.55)
Met
Phase 2
205
Placebo+RN624
(Placebo)
hgxsaswqbt(qoiwoayore) = nctguxgvts pczwrewitx (mtjljltqli, 1.259)
-
03 Aug 2021
(Tanezumab 1 mg)
hgxsaswqbt(qoiwoayore) = bgtpqkllly pczwrewitx (mtjljltqli, 1.337)
Phase 2
1,359
Placebo for naproxen
dcjluspxwf(vdccwkwuzy) = txtzponzqb pckmuefwsk (pqlkjwnhnz, 1.37)
-
07 Jul 2021
Phase 2
59
(Tanezumab)
mhycezobkf(hnxakdgnkr) = znznwsvzax mrtlppsedl (mzmfkrcwbw, 1.02)
-
18 Jun 2021
placebo+tanezumab
(Placebo)
mhycezobkf(hnxakdgnkr) = eozsozjish mrtlppsedl (mzmfkrcwbw, 0.98)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free